Cargando…

A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)

BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Alviggi, Carlo, Revelli, Alberto, Anserini, Paola, Ranieri, Antonio, Fedele, Luigi, Strina, Ida, Massobrio, Marco, Ragni, Nicola, De Placido, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216030/
https://www.ncbi.nlm.nih.gov/pubmed/18053198
http://dx.doi.org/10.1186/1477-7827-5-45
_version_ 1782149096128118784
author Alviggi, Carlo
Revelli, Alberto
Anserini, Paola
Ranieri, Antonio
Fedele, Luigi
Strina, Ida
Massobrio, Marco
Ragni, Nicola
De Placido, Giuseppe
author_facet Alviggi, Carlo
Revelli, Alberto
Anserini, Paola
Ranieri, Antonio
Fedele, Luigi
Strina, Ida
Massobrio, Marco
Ragni, Nicola
De Placido, Giuseppe
author_sort Alviggi, Carlo
collection PubMed
description BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation. METHODS: A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150–300 IU, depending upon patient's age, and underwent a standard IVF procedure. RESULTS: No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients). CONCLUSION: Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety.
format Text
id pubmed-2216030
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22160302008-01-29 A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) Alviggi, Carlo Revelli, Alberto Anserini, Paola Ranieri, Antonio Fedele, Luigi Strina, Ida Massobrio, Marco Ragni, Nicola De Placido, Giuseppe Reprod Biol Endocrinol Research BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation. METHODS: A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150–300 IU, depending upon patient's age, and underwent a standard IVF procedure. RESULTS: No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients). CONCLUSION: Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety. BioMed Central 2007-12-04 /pmc/articles/PMC2216030/ /pubmed/18053198 http://dx.doi.org/10.1186/1477-7827-5-45 Text en Copyright © 2007 Alviggi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Alviggi, Carlo
Revelli, Alberto
Anserini, Paola
Ranieri, Antonio
Fedele, Luigi
Strina, Ida
Massobrio, Marco
Ragni, Nicola
De Placido, Giuseppe
A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title_full A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title_fullStr A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title_full_unstemmed A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title_short A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
title_sort prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of merional (hmg-ibsa) administered subcutaneously versus merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an art programme (ivf)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216030/
https://www.ncbi.nlm.nih.gov/pubmed/18053198
http://dx.doi.org/10.1186/1477-7827-5-45
work_keys_str_mv AT alviggicarlo aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT revellialberto aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT anserinipaola aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT ranieriantonio aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT fedeleluigi aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT strinaida aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT massobriomarco aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT ragninicola aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT deplacidogiuseppe aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT alviggicarlo prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT revellialberto prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT anserinipaola prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT ranieriantonio prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT fedeleluigi prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT strinaida prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT massobriomarco prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT ragninicola prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf
AT deplacidogiuseppe prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf